Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study
Objective: to study the efficacy, immunogenicity, and safety of a 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in patients with rheumatoid arthritis (RA) receiving disease-modifying antirheumatic drugs (DMARDs) and biologic agents (BAs) during a 5-year follow-up.Patients and methods. The...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-12-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/866 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850023473850613760 |
|---|---|
| author | D. V. Bukhanova M. S. Sergeeva B. S. Belov G. M. Tarasova M. V. Cherkasova Yu. A. Muraviev G. V. Lukina N. V. Demidova |
| author_facet | D. V. Bukhanova M. S. Sergeeva B. S. Belov G. M. Tarasova M. V. Cherkasova Yu. A. Muraviev G. V. Lukina N. V. Demidova |
| author_sort | D. V. Bukhanova |
| collection | DOAJ |
| description | Objective: to study the efficacy, immunogenicity, and safety of a 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in patients with rheumatoid arthritis (RA) receiving disease-modifying antirheumatic drugs (DMARDs) and biologic agents (BAs) during a 5-year follow-up.Patients and methods. The investigation included 79 RA patients with a recent history of ≥2 episodes of lower respiratory tract infections (bronchitis, pneumonia). A single dose (0.5 ml) of PPSV-23 was administered subcutaneously during continued methotrexate/leflunomide therapy or 28–30 days before using TNF-α inhibitors. All the patients were followed up during the first year; 39 patients at 24 months (Visit 5), 13 at 36 months (Visit 6), 23 at 48 months (Visit 7), and 18 at 60 months (Visit 8).Results and discussion. RA patients receiving various therapies were noted to have a marked positive immune response to PPSV-23, which was manifested by a significant increase in the postimmunization response coefficient. Vaccination responses were recorded in 61% of the patients with RA. The level of postvaccination responses tended to decrease at the 4-year follow-up. Only one case of community-acquired pneumonia of unknown etiology was detected at 5 years of follow-up.Conclusion. The data obtained by the authors for the first time in the 5-year prospective study indicate the sufficient and long-term immunogenicity, high efficacy, and safety of PPSV-23 in RA patients treated with DMARDs and BAs. Further clinical trials are needed to clarify the influence of various factors on the efficacy and immunogenicity of PPSV-23 and on the degree of their correlation in patients with RA.Objective: to study the efficacy, immunogenicity, and safety of a 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in patients with rheumatoid arthritis (RA) receiving disease-modifying antirheumatic drugs (DMARDs) and biologic agents (BAs) during a 5-year follow-up.Patients and methods. The investigation included 79 RA patients with a recent history of ≥2 episodes of lower respiratory tract infections (bronchitis, pneumonia). A single dose (0.5 ml) of PPSV-23 was administered subcutaneously during continued methotrexate/leflunomide therapy or 28–30 days before using TNF-α inhibitors. All the patients were followed up during the first year; 39 patients at 24 months (Visit 5), 13 at 36 months (Visit 6), 23 at 48 months (Visit 7), and 18 at 60 months (Visit 8).Results and discussion. RA patients receiving various therapies were noted to have a marked positive immune response to PPSV-23, which was manifested by a significant increase in the postimmunization response coefficient. Vaccination responses were recorded in 61% of the patients with RA. The level of postvaccination responses tended to decrease at the 4-year follow-up. Only one case of community-acquired pneumonia of unknown etiology was detected at 5 years of follow-up.Conclusion. The data obtained by the authors for the first time in the 5-year prospective study indicate the sufficient and long-term immunogenicity, high efficacy, and safety of PPSV-23 in RA patients treated with DMARDs and BAs. Further clinical trials are needed to clarify the influence of various factors on the efficacy and immunogenicity of PPSV-23 and on the degree of their correlation in patients with RA. |
| format | Article |
| id | doaj-art-5154c521ec0542b68e26fe35bcccb6a7 |
| institution | DOAJ |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2018-12-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-5154c521ec0542b68e26fe35bcccb6a72025-08-20T03:01:22ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2018-12-01124858810.14412/1996-7012-2018-4-85-882130Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up studyD. V. Bukhanova0M. S. Sergeeva1B. S. Belov2G. M. Tarasova3M. V. Cherkasova4Yu. A. Muraviev5G. V. Lukina6N. V. Demidova7V.A. Nasonova Research Institute of Rheumatology.V.A. Nasonova Research Institute of Rheumatology.V.A. Nasonova Research Institute of Rheumatology.V.A. Nasonova Research Institute of Rheumatology.V.A. Nasonova Research Institute of Rheumatology.V.A. Nasonova Research Institute of Rheumatology.V.A. Nasonova Research Institute of Rheumatology.V.A. Nasonova Research Institute of Rheumatology.Objective: to study the efficacy, immunogenicity, and safety of a 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in patients with rheumatoid arthritis (RA) receiving disease-modifying antirheumatic drugs (DMARDs) and biologic agents (BAs) during a 5-year follow-up.Patients and methods. The investigation included 79 RA patients with a recent history of ≥2 episodes of lower respiratory tract infections (bronchitis, pneumonia). A single dose (0.5 ml) of PPSV-23 was administered subcutaneously during continued methotrexate/leflunomide therapy or 28–30 days before using TNF-α inhibitors. All the patients were followed up during the first year; 39 patients at 24 months (Visit 5), 13 at 36 months (Visit 6), 23 at 48 months (Visit 7), and 18 at 60 months (Visit 8).Results and discussion. RA patients receiving various therapies were noted to have a marked positive immune response to PPSV-23, which was manifested by a significant increase in the postimmunization response coefficient. Vaccination responses were recorded in 61% of the patients with RA. The level of postvaccination responses tended to decrease at the 4-year follow-up. Only one case of community-acquired pneumonia of unknown etiology was detected at 5 years of follow-up.Conclusion. The data obtained by the authors for the first time in the 5-year prospective study indicate the sufficient and long-term immunogenicity, high efficacy, and safety of PPSV-23 in RA patients treated with DMARDs and BAs. Further clinical trials are needed to clarify the influence of various factors on the efficacy and immunogenicity of PPSV-23 and on the degree of their correlation in patients with RA.Objective: to study the efficacy, immunogenicity, and safety of a 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in patients with rheumatoid arthritis (RA) receiving disease-modifying antirheumatic drugs (DMARDs) and biologic agents (BAs) during a 5-year follow-up.Patients and methods. The investigation included 79 RA patients with a recent history of ≥2 episodes of lower respiratory tract infections (bronchitis, pneumonia). A single dose (0.5 ml) of PPSV-23 was administered subcutaneously during continued methotrexate/leflunomide therapy or 28–30 days before using TNF-α inhibitors. All the patients were followed up during the first year; 39 patients at 24 months (Visit 5), 13 at 36 months (Visit 6), 23 at 48 months (Visit 7), and 18 at 60 months (Visit 8).Results and discussion. RA patients receiving various therapies were noted to have a marked positive immune response to PPSV-23, which was manifested by a significant increase in the postimmunization response coefficient. Vaccination responses were recorded in 61% of the patients with RA. The level of postvaccination responses tended to decrease at the 4-year follow-up. Only one case of community-acquired pneumonia of unknown etiology was detected at 5 years of follow-up.Conclusion. The data obtained by the authors for the first time in the 5-year prospective study indicate the sufficient and long-term immunogenicity, high efficacy, and safety of PPSV-23 in RA patients treated with DMARDs and BAs. Further clinical trials are needed to clarify the influence of various factors on the efficacy and immunogenicity of PPSV-23 and on the degree of their correlation in patients with RA.https://mrj.ima-press.net/mrj/article/view/866rheumatoid arthritispneumoniavaccinationpneumococcal vaccine |
| spellingShingle | D. V. Bukhanova M. S. Sergeeva B. S. Belov G. M. Tarasova M. V. Cherkasova Yu. A. Muraviev G. V. Lukina N. V. Demidova Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study Современная ревматология rheumatoid arthritis pneumonia vaccination pneumococcal vaccine |
| title | Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study |
| title_full | Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study |
| title_fullStr | Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study |
| title_full_unstemmed | Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study |
| title_short | Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study |
| title_sort | immunogenicity and efficiency of a 23 valent pneumococcal vaccine in patients with rheumatoid arthritis results of a 5 year follow up study |
| topic | rheumatoid arthritis pneumonia vaccination pneumococcal vaccine |
| url | https://mrj.ima-press.net/mrj/article/view/866 |
| work_keys_str_mv | AT dvbukhanova immunogenicityandefficiencyofa23valentpneumococcalvaccineinpatientswithrheumatoidarthritisresultsofa5yearfollowupstudy AT mssergeeva immunogenicityandefficiencyofa23valentpneumococcalvaccineinpatientswithrheumatoidarthritisresultsofa5yearfollowupstudy AT bsbelov immunogenicityandefficiencyofa23valentpneumococcalvaccineinpatientswithrheumatoidarthritisresultsofa5yearfollowupstudy AT gmtarasova immunogenicityandefficiencyofa23valentpneumococcalvaccineinpatientswithrheumatoidarthritisresultsofa5yearfollowupstudy AT mvcherkasova immunogenicityandefficiencyofa23valentpneumococcalvaccineinpatientswithrheumatoidarthritisresultsofa5yearfollowupstudy AT yuamuraviev immunogenicityandefficiencyofa23valentpneumococcalvaccineinpatientswithrheumatoidarthritisresultsofa5yearfollowupstudy AT gvlukina immunogenicityandefficiencyofa23valentpneumococcalvaccineinpatientswithrheumatoidarthritisresultsofa5yearfollowupstudy AT nvdemidova immunogenicityandefficiencyofa23valentpneumococcalvaccineinpatientswithrheumatoidarthritisresultsofa5yearfollowupstudy |